Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
Yun Shu,1,* Hui Li,2,* Hongjuan Shang,1 Jun Chen,1 Xiaoxing Su,2 Wei Le,1 Yan Lei,2 Liming Tao,1 Cailiang Zou,1 Wendy Wu2 1Department of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang 332000, People’s Republic of China; 2Berry Oncology Corporation, Fuzhou 35...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-10-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/identification-of-a-novel-mprip-ros1-fusion-and-clinical-efficacy-of-c-peer-reviewed-article-OTT |
id |
doaj-ccf9b957a1554552a6e68c67e509bb0f |
---|---|
record_format |
Article |
spelling |
doaj-ccf9b957a1554552a6e68c67e509bb0f2020-11-25T03:38:32ZengDove Medical PressOncoTargets and Therapy1178-69302020-10-01Volume 13103871039158073Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case ReportShu YLi HShang HChen JSu XLe WLei YTao LZou CWu WYun Shu,1,* Hui Li,2,* Hongjuan Shang,1 Jun Chen,1 Xiaoxing Su,2 Wei Le,1 Yan Lei,2 Liming Tao,1 Cailiang Zou,1 Wendy Wu2 1Department of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang 332000, People’s Republic of China; 2Berry Oncology Corporation, Fuzhou 350200, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wendy Wu Email wujy3261@berryoncology.comYun Shu Email shuyun1972@163.comObjective: ROS1 fusions have been identified in 1– 2% of non-small-cell lung cancer (NSCLC) patients; they are validated as a driver of carcinogenesis and could be subjected to inhibition by crizotinib. However, previous studies suggested a variable progression-free survival (PFS) ranging from 9.1 to 20.0 months for crizotinib treatment in ROS1-rearranged NSCLC. Here, we reported a 45-year-old female diagnosed with stage IVB lung adenocarcinoma with multiple lymph nodes and bone metastasis carrying a novel MPRIP-ROS1 fusion, which was identified by RNA-based NGS (next-generation sequencing) and was sensitive to crizotinib treatment.Materials and Methods: A targeted NGS panel was used to analyze genomic DNA and total RNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue block of the patient. An RNA fusion panel based on amplicon sequencing was designed for detection fusion variation. Fusion results were validated using reverse transcriptase polymerase chain reaction and Sanger sequencing.Results: We reported a novel MPRIP-ROS1 fusion identified in this advanced lung adenocarcinoma case. The rearrangement was generated by exons 1– 21 of MPRIP at chr17: p11.2 joined to exons 35– 43 of ROS1 at chr6: q22.1, which retained an intact kinase domain of ROS1. The primary tumor and metastatic lymph nodes were eliminated on computed tomographic (CT) scan imaging after 2 months’ crizotinib treatment, and the multiple bone metastatic lesions were significantly relieved according to bone scintigraphy images. To date, the treatment has lasted 16 months, and the patient is still in follow-up showing sustained response to crizotinib.Conclusion: The study identified a novel MPRIP-ROS1 fusion that was sensitive to crizotinib, which provided a new driver of lung adenocarcinoma and potential therapeutic target for crizotinib. It also expanded NSCLC treatment of ROS1 rearrangement and highlighted the importance of genetic testing for precise treatment decision-making.Keywords: MPRIP-ROS1 fusion, advanced lung adenocarcinoma, sensitive to crizotinib, next-generation sequencinghttps://www.dovepress.com/identification-of-a-novel-mprip-ros1-fusion-and-clinical-efficacy-of-c-peer-reviewed-article-OTTmprip-ros1 fusionadvanced lung adenocarcinomasensitive to crizotinibnext-generation sequencing |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shu Y Li H Shang H Chen J Su X Le W Lei Y Tao L Zou C Wu W |
spellingShingle |
Shu Y Li H Shang H Chen J Su X Le W Lei Y Tao L Zou C Wu W Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report OncoTargets and Therapy mprip-ros1 fusion advanced lung adenocarcinoma sensitive to crizotinib next-generation sequencing |
author_facet |
Shu Y Li H Shang H Chen J Su X Le W Lei Y Tao L Zou C Wu W |
author_sort |
Shu Y |
title |
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report |
title_short |
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report |
title_full |
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report |
title_fullStr |
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report |
title_full_unstemmed |
Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report |
title_sort |
identification of a novel mprip-ros1 fusion and clinical efficacy of crizotinib in an advanced lung adenocarcinoma patient: a case report |
publisher |
Dove Medical Press |
series |
OncoTargets and Therapy |
issn |
1178-6930 |
publishDate |
2020-10-01 |
description |
Yun Shu,1,* Hui Li,2,* Hongjuan Shang,1 Jun Chen,1 Xiaoxing Su,2 Wei Le,1 Yan Lei,2 Liming Tao,1 Cailiang Zou,1 Wendy Wu2 1Department of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang 332000, People’s Republic of China; 2Berry Oncology Corporation, Fuzhou 350200, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wendy Wu Email wujy3261@berryoncology.comYun Shu Email shuyun1972@163.comObjective: ROS1 fusions have been identified in 1– 2% of non-small-cell lung cancer (NSCLC) patients; they are validated as a driver of carcinogenesis and could be subjected to inhibition by crizotinib. However, previous studies suggested a variable progression-free survival (PFS) ranging from 9.1 to 20.0 months for crizotinib treatment in ROS1-rearranged NSCLC. Here, we reported a 45-year-old female diagnosed with stage IVB lung adenocarcinoma with multiple lymph nodes and bone metastasis carrying a novel MPRIP-ROS1 fusion, which was identified by RNA-based NGS (next-generation sequencing) and was sensitive to crizotinib treatment.Materials and Methods: A targeted NGS panel was used to analyze genomic DNA and total RNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue block of the patient. An RNA fusion panel based on amplicon sequencing was designed for detection fusion variation. Fusion results were validated using reverse transcriptase polymerase chain reaction and Sanger sequencing.Results: We reported a novel MPRIP-ROS1 fusion identified in this advanced lung adenocarcinoma case. The rearrangement was generated by exons 1– 21 of MPRIP at chr17: p11.2 joined to exons 35– 43 of ROS1 at chr6: q22.1, which retained an intact kinase domain of ROS1. The primary tumor and metastatic lymph nodes were eliminated on computed tomographic (CT) scan imaging after 2 months’ crizotinib treatment, and the multiple bone metastatic lesions were significantly relieved according to bone scintigraphy images. To date, the treatment has lasted 16 months, and the patient is still in follow-up showing sustained response to crizotinib.Conclusion: The study identified a novel MPRIP-ROS1 fusion that was sensitive to crizotinib, which provided a new driver of lung adenocarcinoma and potential therapeutic target for crizotinib. It also expanded NSCLC treatment of ROS1 rearrangement and highlighted the importance of genetic testing for precise treatment decision-making.Keywords: MPRIP-ROS1 fusion, advanced lung adenocarcinoma, sensitive to crizotinib, next-generation sequencing |
topic |
mprip-ros1 fusion advanced lung adenocarcinoma sensitive to crizotinib next-generation sequencing |
url |
https://www.dovepress.com/identification-of-a-novel-mprip-ros1-fusion-and-clinical-efficacy-of-c-peer-reviewed-article-OTT |
work_keys_str_mv |
AT shuy identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT lih identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT shangh identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT chenj identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT sux identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT lew identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT leiy identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT taol identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT zouc identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport AT wuw identificationofanovelmpripros1fusionandclinicalefficacyofcrizotinibinanadvancedlungadenocarcinomapatientacasereport |
_version_ |
1724541787991703552 |